Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by MPM Bioimpact LLC

MPM Bioimpact LLC increased its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 109.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 459,943 shares of the biotechnology company’s stock after purchasing an additional 240,435 shares during the quarter. MPM Bioimpact LLC’s holdings in Arcturus Therapeutics were worth $7,805,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Virtus ETF Advisers LLC lifted its holdings in shares of Arcturus Therapeutics by 38.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at about $71,000. National Bank of Canada FI raised its holdings in shares of Arcturus Therapeutics by 639.6% in the fourth quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC boosted its position in Arcturus Therapeutics by 22.7% during the fourth quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 2,036 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after buying an additional 3,705 shares during the period. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ARCT. Canaccord Genuity Group reduced their target price on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating on the stock in a report on Tuesday. Wells Fargo & Company dropped their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday, April 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $58.80.

Arcturus Therapeutics Stock Up 2.3%

Arcturus Therapeutics stock opened at $11.86 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 12 month low of $8.04 and a 12 month high of $45.00. The stock has a market cap of $321.66 million, a P/E ratio of -5.34 and a beta of 2.36. The company’s fifty day simple moving average is $11.78 and its 200-day simple moving average is $15.38.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $29.38 million for the quarter, compared to the consensus estimate of $25.64 million. On average, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.